Status:
UNKNOWN
irAE Prediction of Anti-PD-1/L1 in Lung Cancer
Lead Sponsor:
Peking Union Medical College Hospital
Conditions:
Immune Checkpoint Inhibitors
Lung Cancer
Eligibility:
All Genders
18-80 years
Brief Summary
the purpose of this study is to identify multi-dimensional immunological biomarkers including cytokines, autoantibodies, and immune cell subtypes of immune-related adverse events (primary) and prognos...
Detailed Description
After being informed of the study and potential risk, all patients giving written informed consent will undergo peripheral blood sample collection at baseline (before treatment ), 1month and 3month af...
Eligibility Criteria
Inclusion
- 18-80 years of age
- Stage I-IV Lung Cancer confirmed by histopathology or imaging techniques
- Receiving anti-PD-1/anti-PD-L1 immunotherapy (with indication and no contraindication)
Exclusion
- Other cancer treatment
- Other malignancies
Key Trial Info
Start Date :
January 21 2022
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
September 1 2024
Estimated Enrollment :
120 Patients enrolled
Trial Details
Trial ID
NCT05288569
Start Date
January 21 2022
End Date
September 1 2024
Last Update
April 7 2023
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Peking Union Medical College Hospital
Beijing, China